CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid‐seeking behaviour in the rat
- 1 October 2004
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 143 (3) , 343-350
- https://doi.org/10.1038/sj.bjp.0705932
Abstract
We recently provided evidence for a functional link between cannabinoid and opioid endogenous systems in relapse to heroin‐seeking behaviour in rats. In the present study, we aimed at investigating whether the previously observed cross‐talk between cannabinoids and opioids could be extended to mechanisms underlying relapse to cannabinoid‐seeking behaviour after a prolonged period of abstinence. In rats previously trained to intravenously self‐administer the synthetic cannabinoid receptor (CB1) agonist WIN 55,212‐2 (12.5 μg kg−1 inf−1) under a fixed ratio (FR1) schedule of reinforcement, noncontingent nonreinforced intraperitoneal (i.p.) priming injections of the previously self‐administered CB1 agonist (0.25 and 0.5 mg kg−1) as well as heroin (0.5 mg kg−1), but not cocaine (10 mg kg−1), effectively reinstate cannabinoid‐seeking behaviour following 3 weeks of extinction. The selective CB1 receptor antagonist SR 141716A (0.3 mg kg−1 i.p.) does not reinstate responding when given alone, but completely prevents the cannabinoid‐seeking behaviour triggered by WIN 55,212‐2 or heroin primings. The nonselective opioid antagonist naloxone (1 mg kg−1 i.p.) has no effect on operant behaviour per sè, but significantly blocks cannabinoid‐ and heroin‐induced reinstatement of cannabinoid‐seeking behaviour. These results provide the first evidence of drug‐induced reinstatement of cannabinoid‐seeking behaviour, and further strengthen previous findings on a cross‐talk between the endogenous cannabinoid and opioid systems in relapse mechanisms to drug‐seeking. British Journal of Pharmacology (2004) 143, 343–350. doi:10.1038/sj.bjp.0705932Keywords
This publication has 64 references indexed in Scilit:
- Behavioral and molecular changes elicited by acute administration of SR141716 to Δ9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinenceDrug and Alcohol Dependence, 2004
- A Critical Interaction between Dopamine D2 Receptors and Endocannabinoids Mediates the Effects of Cocaine on Striatal GABAergic TransmissionNeuropsychopharmacology, 2004
- Exposure to Δ-9-Tetrahydrocannabinol (THC) Increases Subsequent Heroin Taking but not Heroin's Reinforcing Efficacy: A Self-Administration Study in RatsNeuropsychopharmacology, 2004
- Blockade by the Cannabinoid CB1 Receptor Antagonist, Rimonabant (SR141716), of the Potentiation by Quinelorane of Food-Primed Reinstatement of Food-Seeking BehaviorNeuropsychopharmacology, 2003
- The Cannabinoid CB1 Antagonist N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) Differentially Alters the Reinforcing Effects of Heroin under Continuous Reinforcement, Fixed Ratio, and Progressive Ratio Schedules of Drug Self-Administration in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Chronic Morphine Modulates the Contents of the Endocannabinoid, 2-Arachidonoyl Glycerol, in Rat BrainNeuropsychopharmacology, 2002
- Δ9‐tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effectEuropean Journal of Neuroscience, 2001
- Role of Cannabinoid CB1 Receptor in Morphine Rewarding Effects in MicePharmacy and Pharmacology Communications, 2000
- Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide couplingProstaglandins & Other Lipid Mediators, 1999
- Cannabinoid and Heroin Activation of Mesolimbic Dopamine Transmission by a Common µ 1 Opioid Receptor MechanismScience, 1997